Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
The news page for JanOne Inc. (historically Nasdaq: JAN) provides an archive of company announcements and press releases that document its transition into ALT5 Sigma Corporation and the evolution of its business focus. These news items explain how the organization moved from being described primarily as a biopharmaceutical company focused on non-addicting pain treatments to a multidisciplinary entity combining healthcare initiatives with a growing fintech platform centered on blockchain-powered digital asset services.
Readers will find coverage of the company’s confirmation of its name change to ALT5 Sigma Corporation and ticker change to ALTS, reflecting a strategic realignment to focus on its recently acquired ALT5 Sigma fintech business as a core engine for revenue growth. News articles describe the acquisition and integration of ALT5 Sigma Inc., the company’s addition to the Russell Microcap Index, and subsequent developments such as the launch of the ALT5 Settlement Platform, the introduction of a prepaid Visa card integration, and reported transaction volumes processed by ALT5 subsidiaries.
The archive also includes updates on leadership appointments related to the fintech business, such as the naming of a Chief Revenue Officer and President for ALT5 Sigma, as well as communications about the company’s ongoing biotech activities aimed at addressing the opioid crisis. Earlier releases highlight JanOne’s efforts to develop non-addicting pain treatments and its dedication to funding innovation, technology, and education in this area.
By reviewing the JAN news feed, investors and researchers can trace key milestones, including the acquisition of ALT5 Sigma, strategic realignment decisions, and subsequent product and platform launches in digital payments and digital asset trading. Because the active Nasdaq ticker has changed from JAN to ALTS, this page serves as a historical record of announcements made under the JAN symbol, complementing more recent disclosures filed under the ALT5 Sigma Corporation identity.
ARCA Recycling, a subsidiary of JanOne, has unveiled a new logo and website to reflect its commitment to innovative and environmentally responsible services. In the past year, ARCA recycled over 140,000 appliances, reducing carbon emissions by 136,600 metric tons. The new website features enhanced functionality for better user experience. ARCA aims to diversify its customer base while maintaining its core mission of energy efficiency and environmental protection. The branding update aligns with ARCA's expansion of appliance recycling services and underscores its dedication to a sustainable future.
JanOne Inc. (Nasdaq: JAN) announced an improved formulation of JAN101, developed by Dr. Maureen Donovan at the University of Iowa. This drug targets peripheral artery disease (PAD), affecting over 8.5 million in the U.S. Successful clinical trials demonstrated pain reduction and nerve function improvement. The new formulation aims to further enhance these benefits and will be used in upcoming pivotal clinical trials, with manufacturing by CoreRx set to begin soon.
ARCA Recycling, Inc., a subsidiary of JanOne, has announced the opening of three new recycling centers in Kent, Washington; Tulare, California; and Hainesport, New Jersey. These centers aim to enhance ARCA's recycling operations and customer service across North America. The Hainesport facility will feature advanced appliance processing technology for efficient material compaction, reducing transportation costs and carbon footprint. This expansion will also generate local jobs and support various recycling programs for both residential and commercial clients.
JanOne Inc. (Nasdaq: JAN) announced the issuance of U.S. Patent 11,247,902 B2 for a method to enhance nerve function using JAN101, a potential treatment for peripheral artery disease (PAD) affecting millions. This patent strengthens JanOne's position in the market by allowing JAN101 to address nerve damage from microvascular disease, a significant complication of PAD. The patent is exclusively licensed to JanOne and was co-discovered by leading researchers. The company continues to pursue innovations aimed at combating pain without addiction.
JanOne Inc. (Nasdaq: JAN) has sold the majority of its subsidiary, GeoTraq Inc., to SPYR Technologies Inc. for $13.5 million. The transaction involves cash and 30 million shares of SPYR's common stock. CEO Tony Isaac emphasized that this sale enables JanOne to concentrate on its primary business of developing non-addictive pain-relief drugs, particularly JAN101, aimed at treating peripheral artery disease (PAD). The sale is expected to assist in funding necessary clinical trials for JAN101.
JanOne Inc. (Nasdaq: JAN) is advancing research on treatments for methamphetamine use disorder through a novel strategy involving the Translocator Protein 18 kDa (TSPO). Despite a decline in meth use among younger individuals, usage has surged by 13% annually in those over 26, leading to over 150,000 new users each year. The overdose death rate has increased by 300% in the last decade. With a market projected at $500M and no FDA-approved drugs for treatment, JanOne's initiatives could significantly impact the opioid crisis, as over 40% of meth users also abuse opioids.
ARCA Recycling, a subsidiary of JanOne (NASDAQ: JAN), secured a $1.6 million contract for appliance recycling services in Virginia and North Carolina. This program aims to retire low-efficiency refrigerators and freezers and will continue until 2023. ARCA will recycle the collected appliances at its Northeastern U.S. centers, adhering to EPA guidelines. As the largest implementer of appliance recycling initiatives in North America, ARCA operates over 100 programs.
JanOne Inc. (NASDAQ: JAN) announced an option agreement with LSU Health Shreveport for a novel strategy to combat methamphetamine use disorder (MUD) by activating the Translocator Protein 18 kDa (TSPO). This agreement allows JanOne to explore new drug compounds targeting TSPO, aiming to reduce cravings for meth. The company's drug discovery program is set to begin in 2022, with a preclinical candidate expected in 2023. JanOne also plans to initiate a Phase 2b trial for its pain treatment drug, JAN101, by late 2022.
ARCA Recycling, a subsidiary of JanOne (NASDAQ: JAN), has launched two new appliance recycling programs in Northern California aimed at reducing greenhouse gas and ozone-depleting emissions. These initiatives are expected to recycle 10,000 appliances, diverting over 1.2 million lbs. of recyclable materials and preventing the release of over 1,000 ODP-weighted kg. of harmful substances. The recycling process adheres to U.S. EPA standards, ensuring the safe removal of hazardous materials.
ARCA Recycling, a subsidiary of JanOne (NASDAQ: JAN), has experienced significant growth in its appliance replacement programs, securing contracts worth over $3 million this year. These contracts could boost revenue to approximately $20 million in 2021. The programs aim to replace inefficient appliances with ENERGY STAR®-certified models for income-qualified customers across multiple states. Operating over 40 programs and replacing around 30,000 appliances annually, ARCA is focused on reducing energy costs and greenhouse gas emissions in disadvantaged communities.